Hanmi Pharmaceutical Sungki-Lim & Chongyoon-Lim Signed and Concluded the Public Medical Research and Development Agreement with Fondazione Policlinico Universitario Agostino Gemelli of Rome, Italy

Establish “Woman Centre” for prenatal and postnatal management in Rome and set up a new practice course for nursing.

On October 5, 2017, Hanmi Pharmaceutical signed and concluded a cooperative research and development agreement for public medical service of South Korea and Italy with Fondazione Policlinico Universitario Agostino Gemelli (IRCCS) and Università Cattolica del Sacro Cuore. The key point of the agreement is the research and development (R&D) of the common society focus in South Korea and Italy, i.e. low birthrate, newborn health, systematic prenatal and postnatal management and other research topics.

It’s worth noting that the professional discipline of nursing in the Università Cattolica del Sacro Cuore set up the practice course to systematize South Korea’s prenatal management system and increase the research on women and babies health. Besides, the “Woman Centre” was decided to be established to set up new educational curriculum. The agreement makes sense that Italian educational/medical institutions first accepted South Korea’s postnatal management culture and began to pay attention to the public postnatal nursing school which gradually became the domestic public welfare policy in South Korea. The Università Cattolica del Sacro Cuore has cultivated the first black minister Cecile Kyenge in the Italian government, which is a university with distinguished achievement in the field of medicine, politics and economics. Fondazione Policlinico Universitario Agostino Gemelli, is well known by the world as the hospital where Pope John Paul II was treated.
For the purpose of signing the agreement, “Sungki-Lim”, president of Hanmi Pharm. Co., Ltd. and “Chongyoon-Lim”, representative of Hanmi Science visited Rome, Chongyoon-Lim said, “Declaration of the Rights of the Child formulated by the UN stipulated that: the puerperae and children before and after delivery have the right to receive adequate social protection and management. This agreement is the spiritual power for the UN, and the exploration for the efforts and fusion of eastern and western learning in public welfare.”

Chongyoon-Lim has been promoting confinement center and infant milk powder business in South Korea and China. In August of last year, a high-end confinement center – “CENTRE OFMOM” was set up in Beijing. In the meanwhile, the COREE S.r.l Enterprise managed by him in Italy for the purpose of promoting the development in infant products and dairy products like liquid formula for children has already been undertaking the R&D working with the research teams of Università Cattolica del Sacro  Cuore and Fondazione Policlinico Universitario Agostino Gemelli since 2015.

LuoYuanchang, the councilor of South Korea Embassy in Italy, who attended the signing ceremony, said, “It is the first cooperation of South Korean pharmaceutical enterprise and Italian hospital, the cooperation on public medical service and R&D not only brings a profound implications for political diplomacy, but also further deepens cultural and academic exchanges of two countries.”

Source of the article:Hanmi Pharm. Co., Ltd. — Sungki-Lim & Chongyoon-Lim signed and concluded the public medical research and development agreement with Fondazione Policlinico Universitario Agostino Gemelli of Rome, Italy  | LAWISSUE

Contact us
Ofmom Italy |Coree Srl
Piazza S. Babila 5, 20122 Milan, Italy

 

+39 02 36636 376
info@ofmom.it

For further information on the proper intake of the products, it is advisable to always contact your doctor or pharmacist.
The information on this site cannot in any way replace the direct relationship between health professional and patient. It is therefore necessary to always consult your doctor and / or pharmacist.